High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):843-6. doi: 10.1080/17425255.2016.1198318. Epub 2016 Jun 17.

Andrea Santamato¹, Maurizio Ranieri¹, Vincenzo Solfrizzi², Madia Lozupone³, Michele Vecchio⁴, Antonio Daniele⁵, Antonio Greco⁶, Davide Seripa⁶, Giancarlo Logroscino^{3

7}, Francesco Panza^{3

6

7}

¹ a Physical Medicine and Rehabilitation Section-'OORR Hospital' , University of Foggia , Foggia , Italy.
² b Geriatric Medicine-Memory Unit and Rare Disease Centre , University of Bari Aldo Moro , Bari , Italy.
³ c Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, and Sense Organs , University of Bari Aldo Moro , Bari , Italy.
⁴ d Department of Medical Sciences , UOC Physical Medicine and Rehabilitation, AOU 'O.V.E-Policlinico' , Catania , Italy.
⁵ e Institute of Neurology , Catholic University of Sacred Heart , Rome , Italy.
⁶ f Gerontology-Geriatrics Research Laboratory , IRCCS Casa Sollievo della Sofferenza , Foggia , Italy.
⁷ g Department of Clinical Research in Neurology , University of Bari Aldo Moro, 'Pia Fondazione Cardinale G. Panico' , Lecce , Italy.

No abstract available

Keywords: Upper motor neuron syndrome; adverse effects; botulinum toxin type A; incobotulinumtoxinA; safety; spasticity; stroke.

MeSH terms